Mostrar el registro sencillo del ítem

dc.contributor.authorMarchal, JA
dc.contributor.authorLopez, GJ
dc.contributor.authorPeran, M
dc.contributor.authorComino, A
dc.contributor.authorDelgado, JR
dc.contributor.authorGarcia-Garcia, JA
dc.contributor.authorConde, V
dc.contributor.authorAranda, FM
dc.contributor.authorRivas ?, Carmen
dc.contributor.authorEsteban, M
dc.contributor.authorGarcia, MA
dc.date.accessioned2017-06-07T07:34:59Z
dc.date.available2017-06-07T07:34:59Z
dc.date.issued2014
dc.identifier.issn0892-6638
dc.identifier.urihttp://hdl.handle.net/20.500.11940/8207
dc.description.abstractAn inverse association between cancer and neurodegeneration is plausible because these biological processes share several genes and signaling pathways. Whereas uncontrolled cell proliferation and decreased apoptotic cell death governs cancer, excessive apoptosis contributes to neurodegeneration. Protein kinase R (PKR), an interferon-inducible double-stranded RNA protein kinase, is involved in both diseases. PKR activation blocks global protein synthesis through eIF2alpha phosphorylation, leading to cell death in response to a variety of cellular stresses. However, PKR also has the dual role of activating the nuclear factor kappa-B pathway, promoting cell proliferation. Whereas PKR is recognized for its negative effects on neurodegenerative diseases, in part, inducing high level of apoptosis, the role of PKR activation in cancer remains controversial. In general, PKR is considered to have a tumor suppressor function, and some clinical data show a correlation between suppressed or inactivated PKR and a poor prognosis for several cancers. However, other studies show high PKR expression and activation levels in various cancers, suggesting that PKR might contribute to neoplastic progression. Understanding the cellular factors and signals involved in the regulation of PKR in these age-related diseases is relevant and may have important clinical implications. The present review highlights the current knowledge on the role of PKR in neurodegeneration and cancer, with special emphasis on its regulation and clinical implications.
dc.language.isoeng
dc.subject.meshAnimals
dc.subject.meshApoptosis
dc.subject.meshCell Proliferation
dc.subject.meshDisease Progression
dc.subject.meshGene Expression Regulation, Enzymologic
dc.subject.meshHumans
dc.subject.meshInflammation
dc.subject.meshMicroRNAs
dc.subject.meshNF-kappa B
dc.subject.meshNeoplasms
dc.subject.meshNeurodegenerative Diseases
dc.subject.meshPhosphorylation
dc.subject.meshPrognosis
dc.subject.meshProtein Processing, Post-Translational
dc.subject.meshTumor Suppressor Protein p53
dc.titleThe impact of PKR activation: from neurodegeneration to cancer
dc.typeArtigoes
dc.authorsophosMarchal, JA
dc.authorsophosLopez, GJ
dc.authorsophosPeran, M
dc.authorsophosComino, A
dc.authorsophosDelgado, JR
dc.authorsophosGarcia-Garcia, JA
dc.authorsophosConde, V
dc.authorsophosAranda, FM
dc.authorsophosRivas, C
dc.authorsophosEsteban, M
dc.authorsophosGarcia, MA
dc.identifier.doi10.1096/fj.13-248294
dc.identifier.isi335336000002
dc.identifier.pmid24522206
dc.identifier.sophos16314
dc.issue.number5
dc.journal.titleFASEB JOURNAL
dc.organizationServizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::EOXI de Santiago::IDIS.- Instituto de investigaciones sanitarias de Santiago
dc.page.initial1965
dc.page.final1974
dc.rights.accessRightsopenAccess
dc.typesophosArtículo de Revisión
dc.volume.number28


Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem